Home › News › Compounded Glutathione Recall Over Elevated Endotoxin Levels

Compounded Glutathione Recall Over Elevated Endotoxin Levels

August 6, 2026 · 1 source · 4 min read

Compounding & Supply Safety & Regulation

A detailed shot of white capsules in a black bowl, highlighting healthcare concerns. — Glass multi-dose injection vial on a clinical counter with a pharmacy label showing a lot number — Photo: ready made / Pexels

An Austin, Texas compounding pharmacy has pulled specified lots of an injectable antioxidant preparation after its own testing flagged a contaminant that sterility testing does not catch. The compounded glutathione recall reaches the patient level, which means vials already dispensed to individuals are covered.

Victory Medical Center Pharmacy is voluntarily recalling certain lots of Compounded Glutathione 200 mg/mL multi-dose vials nationwide, down to the patient level, after pharmacy testing found elevated bacterial endotoxin levels. The FDA published the company's announcement on August 5, 2026. Endotoxin limits apply to injectables because these heat-stable bacterial cell-wall fragments survive sterilisation.

The short version

Victory Medical Center Pharmacy of Austin, Texas is voluntarily recalling certain lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials nationwide, and the FDA posted the announcement on August 5, 2026.
The stated reason is elevated bacterial endotoxin levels identified by the pharmacy's own testing, not a sterility failure.
The recall is designated to the patient level, so vials already in the hands of individuals and clinics are within its scope.
Bacterial endotoxins are heat-stable fragments of gram-negative bacterial cell walls, which is why injectables are tested against numeric endotoxin limits separately from sterility.
Anyone holding clinic-supplied injectables can check the lot number printed on the vial or pharmacy label against the list in the FDA posting.

What was recalled, and why

Victory Medical Center Pharmacy, a compounding pharmacy in Austin, Texas, announced a voluntary nationwide recall of certain lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials. The FDA published the company's announcement through its recalls, market withdrawals and safety alerts page on August 5, 2026. According to that announcement, the recall was initiated because pharmacy testing identified elevated bacterial endotoxin levels in the product.

The recall is designated to the patient level. In FDA terminology that is the deepest reach a recall can have: rather than stopping at wholesalers or at the clinics that bought the product, it covers vials already dispensed to individuals. Practically, that means the specific lot numbers listed in the announcement are the ones a person needs to compare against the label on any vial they still hold.

What is compounded glutathione?

Glutathione is a small peptide built from three amino acids — glutamate, cysteine and glycine — that the body makes on its own and that functions in cellular antioxidant defence. Injectable preparations of it are supplied largely by compounding pharmacies and administered or dispensed through wellness, longevity and IV-therapy clinics rather than sold as an approved finished drug product from a pharmaceutical manufacturer.

That distinction is the heart of this story. A compounded preparation is made by a pharmacy for patients rather than manufactured under an approved application that the FDA has reviewed for safety, effectiveness and manufacturing quality before it reaches the market. Many people who track a peptide protocol receive other injectables from the same clinic or pharmacy channel, which is why a recall like this one is worth reading even if glutathione is not the substance you are logging.

Recalls are the clearest argument for inventory tracking that records lot numbers and vial-open dates rather than just what is left in the fridge.

Why do elevated endotoxin levels matter in an injectable?

Bacterial endotoxins are lipopolysaccharide fragments from the outer membrane of gram-negative bacteria. They remain after the bacteria themselves are dead, and they are heat-stable, so a product can pass a sterility test and still carry endotoxin above the accepted limit. For that reason, compendial standards set numeric endotoxin limits for products intended for injection, and endotoxin testing is performed separately from sterility testing.

The announcement as published by the FDA credits the finding to the pharmacy's own testing and describes the action as voluntary. That is a common pattern in compounded-product recalls: release testing, or a test performed on a retained sample, flags a result after product has already shipped, and the compounder then has to reach every clinic and patient who received the affected lots.

Dated side-effect logging is what lets you line up anything unusual against the window a specific vial was in use.

Multi-dose vials and how long the exposure window runs

A multi-dose vial is designed to be entered more than once and drawn from over a period of days or weeks, which is why such vials contain a preservative. If a contaminant such as endotoxin was present when the vial was compounded, it is present in every withdrawal from that vial rather than in a single one. The relevant window is therefore however long a given vial stayed in use.

For anyone keeping a written or app-based record, that is the detail with practical value here: which vial, from which lot, was in use on which dates. A record like that turns a vague recall notice into a specific question a clinician can actually answer, instead of a guess about whether a particular product was involved.

Multi-dose vials rely on a preservative to tolerate repeated entry, the same principle behind what bacteriostatic water is and why it differs from sterile water.

How do you tell whether your vial is part of the recall?

Lot numbers and expiry dates are printed on the vial itself and usually repeated on the pharmacy's dispensing label. The FDA posting carries the list of affected lots and the pharmacy's contact information for the recall. Questions about a specific vial — whether it matches, and what to do with it — belong with the prescribing clinician or the pharmacy that dispensed it, both of which are contactable through the notice.

The FDA also asks that adverse events and quality problems associated with products like this be reported through MedWatch, its voluntary reporting programme. Reporting is how quality signals get connected across states and clinics; a single patient report is often the reason a pattern becomes visible at all in the compounded-product space, where there is no manufacturer-scale pharmacovigilance system behind each item.

Compounded sterile injectables: 503A pharmacies and 503B outsourcing facilities

US compounding falls into two regulatory buckets. A traditional pharmacy compounding under section 503A of the Federal Food, Drug, and Cosmetic Act prepares products for identified patients with a prescription and is exempt from certain requirements that apply to manufacturers, including premarket approval and full current good manufacturing practice rules. A 503B outsourcing facility registers with the FDA, can make batches without patient-specific prescriptions, must follow CGMP, and is subject to FDA inspection.

Neither category involves the FDA reviewing a specific compounded product before it is sold, so quality assurance depends heavily on the facility's own testing and processes. That is the structural reason recalls in this space usually surface either through the compounder's testing, as here, or through an FDA inspection — and the reason a patient may learn about one from an agency alerts page rather than from the clinic that supplied the vial.

What this means if you're tracking a protocol

If you keep an inventory of what you inject, this recall is a test of whether that record is complete. Lot number, expiry date, the pharmacy or clinic that supplied it, and the dates a particular vial was open are the four fields that let you resolve a recall notice in a minute rather than an afternoon. Non-peptide injectables obtained from the same clinic — antioxidant preparations, vitamin blends, anything else in the refrigerator — belong in the same log for exactly this reason.

The second practical consequence involves symptom records. A recall to the patient level covers a defined date range of product, and anything you noted during the window a specific vial was in use becomes information your prescriber can weigh, rather than a recollection. Nothing here changes what any individual should do with a protocol; that is a conversation with the clinician who wrote the prescription and with the pharmacy named in the notice.

Frequently asked questions

What does a recall to the patient level mean?

A recall to the patient level is the deepest level of a recall's reach. Instead of stopping at distributors, wholesalers or the clinics that purchased the product, it covers units already dispensed to individual patients. In the Victory Medical Center Pharmacy compounded glutathione recall announced through the FDA on August 5, 2026, that means vials held at home or at a clinic are both within scope.

Is bacterial endotoxin the same thing as bacterial contamination?

Not exactly. Endotoxins are lipopolysaccharide fragments from the outer membrane of gram-negative bacteria, and they persist after the organisms are killed. Because they are heat-stable, a product can be sterile — free of viable organisms — and still contain endotoxin above the accepted limit. That is why injectable products are tested against numeric endotoxin limits separately from sterility testing.

Does this recall affect compounded semaglutide or tirzepatide?

No. The recall covers specified lots of one product, Compounded Glutathione 200 mg/mL Multi-Dose Vials, from one pharmacy in Austin, Texas. It says nothing about compounded GLP-1 preparations from other facilities. It does illustrate the general quality-assurance question that applies to any compounded sterile injectable, since these products are not reviewed by the FDA before they are dispensed.

How do I report a problem with a compounded injectable to the FDA?

The FDA collects reports of adverse events and product quality problems through MedWatch, its voluntary reporting programme, which accepts submissions from patients as well as clinicians. Reports can describe a reaction, a suspected contamination, or a labelling or appearance problem. Clinical questions about your own situation still go to your prescriber; MedWatch exists so the agency can detect patterns across multiple reports.

Sources

Victory Medical Center Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levels
FDA MedWatch Safety Alerts · August 5, 2026

How this page is made. PeptideWiz News covers regulatory actions, published research, and industry developments from a fixed list of primary sources — the FDA, NIH, EMA, ClinicalTrials.gov, PubMed, peer-reviewed journals, and company press rooms. Articles are drafted with AI assistance from those sources, reviewed before publication, and always link to the original. Read the full editorial standards & corrections policy. This is journalism about peptides, not medical advice: it does not recommend any substance, does not state dosages, and is not a substitute for your provider.

← Back to all peptide news